All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
PET-guided BrECADD for the treatment of advanced-stage cHL
Bookmark this article
|
Results from the phase III, open label, HD21 trial (NCT02661503) evaluating efficacy and tolerability of positron emission tomography (PET)-guided brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD) versus bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) in newly diagnosed, advanced-stage, classical Hodgkin lymphoma were published by Borchmann et al.1 in The Lancet. |
| Key learnings: |
|
The 4-year progression-free survival rate was higher in the BrECADD arm compared with eBEACOPP arm (94.3% vs 90.9%; hazard ratio, 0.66; p = 0.035). |
| Treatment with BrECADD also resulted in lower rates of ≥1 treatment-related morbidity event compared with eBEACOPP (42% vs 59%; relative risk, 0.72; p < 0.0001). |
|
Patients in the BrECADD arm had a higher 4-year event-free survival rate compared with those in the eBEACOPP arm (91.4% vs 88.2%). |
| Overall survival rates were comparable between the BreCADD and eBEACOPP arms (98.6% and 98.2%, respectively). |
| The findings from the study show that BrECADD is better tolerated and more effective than eBEACOPP in the treatment of advanced stage classical Hodgkin lymphoma, and could become a potential standard fist-line treatment option in this patient population. |
|
The utilization of PET-guided BrECADD therapy allows for personalized treatment intensity, potentially reducing over-treatment and the associated toxicities. |
- Borchmann P, Ferdinandus J, Schneider G, et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet. 2024;404(10450):341-352. DOI: 10.1016/S0140-6736(24)01315-1
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
44 votes - 79 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox